• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Benzophenanthridine alkaloids Dihydrobenzophenanthridine alkaloids

Recent Advances in the Study of 6-Methoxydihydrosanguinarine (CAS: 72401-54-8)

6-Methoxydihydrosanguinarine (CAS: 72401-54-8), a derivative of the benzophenanthridine alkaloid family, has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, known for its unique structural and pharmacological properties, has been the subject of numerous studies aimed at exploring its potential therapeutic applications. The following research brief synthesizes the latest findings on 6-Methoxydihydrosanguinarine, focusing on its biological activities, mechanisms of action, and potential clinical implications.

Recent studies have highlighted the compound's promising anticancer properties. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 6-Methoxydihydrosanguinarine exhibits potent cytotoxic effects against a range of cancer cell lines, including breast, lung, and colon cancers. The researchers employed a combination of in vitro assays and molecular docking simulations to elucidate the compound's interaction with key cellular targets, such as topoisomerase II and the PI3K/AKT signaling pathway. These findings suggest that 6-Methoxydihydrosanguinarine may serve as a lead compound for the development of novel anticancer agents.

In addition to its anticancer potential, 6-Methoxydihydrosanguinarine has also been investigated for its anti-inflammatory and antimicrobial activities. A recent study in the European Journal of Pharmacology (2024) reported that the compound significantly reduces the production of pro-inflammatory cytokines, such as TNF-α and IL-6, in macrophage cells. Furthermore, the study revealed that 6-Methoxydihydrosanguinarine exhibits broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. These findings underscore the compound's potential as a multi-target therapeutic agent.

The pharmacokinetic profile of 6-Methoxydihydrosanguinarine has also been a focus of recent research. A 2024 study published in Drug Metabolism and Disposition utilized advanced LC-MS/MS techniques to characterize the compound's absorption, distribution, metabolism, and excretion (ADME) properties in rodent models. The results indicated that 6-Methoxydihydrosanguinarine has favorable bioavailability and a relatively long half-life, making it a viable candidate for further drug development. However, the study also identified potential metabolic pathways that could lead to the formation of reactive metabolites, highlighting the need for further optimization to improve safety profiles.

Despite these promising findings, challenges remain in the clinical translation of 6-Methoxydihydrosanguinarine. Issues such as solubility, stability, and potential off-target effects need to be addressed through structural modifications and formulation strategies. Recent advances in nanotechnology-based drug delivery systems, as reported in a 2023 study in the International Journal of Pharmaceutics, offer potential solutions to these challenges. The study demonstrated that encapsulating 6-Methoxydihydrosanguinarine in polymeric nanoparticles significantly enhances its solubility and targeted delivery to tumor tissues.

In conclusion, 6-Methoxydihydrosanguinarine (CAS: 72401-54-8) represents a promising candidate for the development of novel therapeutic agents with diverse pharmacological activities. Ongoing research efforts are focused on optimizing its chemical structure, improving its pharmacokinetic properties, and exploring its potential in combination therapies. As the scientific community continues to unravel the molecular mechanisms underlying its biological effects, 6-Methoxydihydrosanguinarine is poised to play a significant role in the future of chemical biology and pharmaceutical innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)